Soligenix (NASDAQ: SNGX) is one of 95 public companies in the “Biotechnology” industry, but how does it contrast to its rivals? We will compare Soligenix to similar companies based on the strength of its earnings, institutional ownership, dividends, profitability, valuation, analyst recommendations and risk.

Profitability

This table compares Soligenix and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Soligenix -86.15% -129.88% -74.33%
Soligenix Competitors -912.91% -186.15% -28.31%

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Soligenix and its rivals, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Soligenix 0 0 2 0 3.00
Soligenix Competitors 122 460 1151 11 2.60

Soligenix currently has a consensus target price of $8.00, suggesting a potential upside of 252.42%. As a group, “Biotechnology” companies have a potential upside of 47.86%. Given Soligenix’s stronger consensus rating and higher possible upside, equities analysts plainly believe Soligenix is more favorable than its rivals.

Insider & Institutional Ownership

2.0% of Soligenix shares are owned by institutional investors. Comparatively, 20.4% of shares of all “Biotechnology” companies are owned by institutional investors. 5.0% of Soligenix shares are owned by company insiders. Comparatively, 19.6% of shares of all “Biotechnology” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Valuation and Earnings

This table compares Soligenix and its rivals revenue, earnings per share (EPS) and valuation.

Gross Revenue EBITDA Price/Earnings Ratio
Soligenix $6.98 million -$6.76 million -1.67
Soligenix Competitors $224.58 million $58.11 million -1.06

Soligenix’s rivals have higher revenue and earnings than Soligenix. Soligenix is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Volatility and Risk

Soligenix has a beta of 2.25, suggesting that its stock price is 125% more volatile than the S&P 500. Comparatively, Soligenix’s rivals have a beta of 1.13, suggesting that their average stock price is 13% more volatile than the S&P 500.

About Soligenix

Soligenix, Inc. is a late-stage biopharmaceutical company. The Company is focused on developing and commercializing products to treat rare diseases. The Company operates through two segments: BioTherapeutics and Vaccines/BioDefense. Its BioTherapeutics segment is developing a photodynamic therapy (SGX301) utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL), formulations of oral beclomethasone 17,21-dipropionate (BDP) for the prevention/treatment of gastrointestinal (GI) disorders characterized by severe inflammation, and its innate defense regulator (IDR) technology, dusquetide (SGX942) for the treatment of oral mucositis in head and neck cancer. Its Vaccines/BioDefense business segment includes active development programs for RiVax, its ricin toxin vaccine candidate, OrbeShield, its GI acute radiation syndrome (GI ARS) therapeutic candidate, and SGX943, its melioidosis therapeutic candidate.

Receive News & Ratings for Soligenix Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Soligenix Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.